Health Care [ 3/12 ] | Biotechnology [ 8/75 ]
NASDAQ | Common Stock
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors.
In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease.
Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A.
The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx.
Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 17, 26 | 0.21 Decreased by -75.00% | 0.37 Decreased by -43.24% |
| Nov 6, 25 | 0.65 Increased by +124.14% | 0.45 Increased by +44.44% |
| Aug 7, 25 | 0.54 Increased by +68.75% | 0.34 Increased by +58.82% |
| May 8, 25 | 0.31 Increased by +6.90% | 0.23 Increased by +34.78% |
| Feb 12, 25 | 0.84 Increased by +500.00% | 0.28 Increased by +200.00% |
| Nov 6, 24 | 0.29 Decreased by -36.96% | 0.33 Decreased by -12.12% |
| Aug 8, 24 | 0.32 Increased by +6.67% | 0.32 |
| May 2, 24 | 0.29 Increased by +480.00% | 0.14 Increased by +107.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 6.72 B Increased by +4.38% | 196.98 M Decreased by -94.88% | Increased by +2.93% Decreased by -95.09% |
| Sep 30, 25 | 1.02 B Decreased by -81.55% | 401.00 M Decreased by -68.33% | Increased by +39.24% Increased by +71.70% |
| Jun 30, 25 | 5.86 B Increased by +652.47% | 2.13 B Increased by +948.89% | Increased by +36.32% Increased by +39.39% |
| Mar 31, 25 | 715.00 M Increased by +18.57% | 195.00 M Increased by +1.56% | Increased by +27.27% Decreased by -14.35% |
| Dec 31, 24 | 6.44 B Increased by +37.69% | 3.85 B Increased by +500.78% | Increased by +59.70% Increased by +336.34% |
| Sep 30, 24 | 5.54 B Increased by +17.57% | 1.27 B Decreased by -39.83% | Increased by +22.85% Decreased by -48.82% |
| Jun 30, 24 | 779.00 M Decreased by -81.31% | 203.00 M Decreased by -84.79% | Increased by +26.06% Decreased by -18.62% |
| Mar 31, 24 | 603.00 M Decreased by -78.72% | 192.00 M Decreased by -8.57% | Increased by +31.84% Increased by +329.70% |